FIRST-LINE ATEZOLIZUMAB PLUS CHEMOTHERAPY IN CHEMOTHERAPY-NAÏVE PATIENTS WITH ADVANCED NSCLC: A PHASE III CLINICAL PROGRAM.
確定! 回上一頁